Diabetes Care. 2018 Dec;41(12):2471-2479. doi: 10.2337/dc18-1437. Epub 2018 Oct 16.
To compare glycemic control, quality of life, and pregnancy outcomes of women using insulin pumps and multiple daily injection therapy (MDI) during the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT).
This was a prespecified analysis of CONCEPTT involving 248 pregnant women from 31 centers. Randomization was stratified for pump versus MDI and HbA. The primary outcome was change in HbA from randomization to 34 weeks' gestation. Key secondary outcomes were continuous glucose monitoring (CGM) measures, maternal-infant health, and patient-reported outcomes.
At baseline, pump users were more often in stable relationships ( = 0.003), more likely to take preconception vitamins ( = 0.03), and less likely to smoke ( = 0.02). Pump and MDI users had comparable first-trimester glycemia: HbA 6.84 ± 0.71 vs. 6.95 ± 0.58% (51 ± 7.8 vs. 52 ± 6.3 mmol/mol) ( = 0.31) and CGM time in target (51 ± 14 vs. 50 ± 13%) ( = 0.40). At 34 weeks, MDI users had a greater decrease in HbA (-0.55 ± 0.59 vs. -0.32 ± 0.65%, = 0.001). At 24 and 34 weeks, MDI users were more likely to achieve target HbA ( = 0.009 and = 0.001, respectively). Pump users had more hypertensive disorders ( = 0.011), mainly driven by increased gestational hypertension (14.4 vs. 5.2%; = 0.025), and more neonatal hypoglycemia (31.8 vs. 19.1%, = 0.05) and neonatal intensive care unit (NICU) admissions >24 h (44.5 vs. 29.6%; = 0.02). Pump users had a larger reduction in hypoglycemia-related anxiety ( = 0.05) but greater decline in health/well-being ( = 0.02).
In CONCEPTT, MDI users were more likely to have better glycemic outcomes and less likely to have gestational hypertension, neonatal hypoglycemia, and NICU admissions than pump users. These data suggest that implementation of insulin pump therapy is potentially suboptimal during pregnancy.
比较在 1 型糖尿病女性连续血糖监测妊娠试验(CONCEPTT)中使用胰岛素泵和多次每日注射治疗(MDI)的女性的血糖控制、生活质量和妊娠结局。
这是 CONCEPTT 的一项预设分析,涉及来自 31 个中心的 248 名孕妇。随机分为泵组与 MDI 组和 HbA 分层。主要结局是从随机化到 34 周妊娠时 HbA 的变化。关键次要结局是连续血糖监测(CGM)指标、母婴健康和患者报告的结局。
在基线时,泵使用者更常处于稳定的关系中(=0.003),更有可能服用孕前维生素(=0.03),并且不太可能吸烟(=0.02)。泵和 MDI 使用者的孕早期血糖相当:HbA 6.84±0.71% vs. 6.95±0.58%(51±7.8 vs. 52±6.3mmol/mol)(=0.31)和 CGM 时间在目标范围内(51±14% vs. 50±13%)(=0.40)。在 34 周时,MDI 使用者的 HbA 下降更大(-0.55±0.59% vs. -0.32±0.65%,=0.001)。在 24 周和 34 周时,MDI 使用者更有可能达到目标 HbA(=0.009 和=0.001,分别)。泵使用者更易发生高血压疾病(=0.011),主要由妊娠高血压(14.4% vs. 5.2%;=0.025)引起,新生儿低血糖(31.8% vs. 19.1%,=0.05)和新生儿重症监护病房(NICU)入住>24 小时(44.5% vs. 29.6%;=0.02)的发生率更高。泵使用者低血糖相关焦虑症(=0.05)的减少幅度更大,但健康/幸福感(=0.02)的下降幅度更大。
在 CONCEPTT 中,与泵使用者相比,MDI 使用者的血糖控制结果更优,发生妊娠高血压、新生儿低血糖和 NICU 入住的可能性更低。这些数据表明,在妊娠期间胰岛素泵治疗的实施可能并不理想。